Preview

Rational Pharmacotherapy in Cardiology

Advanced search

COMPARATIVE EVALUATION OF EFFICACY AND TOLERABILITY OF ORIGINAL AND GENERIC BISOPROLOL IN PATIENTS WITH ARTERIAL HYPERTENSION 1-2 GRADE

https://doi.org/10.20996/1819-6446-2007-3-3-15-21

Full Text:

Abstract

Aim. To study a clinical equivalence of two medications of bisoprolol in patients with arterial hypertension (AH) 1-2 grades.

Methods. Efficacy and tolerability of original (Concor, NYCOMED, Merck KGaA) and generic (Bisogamma, WORWAG PHARMA GmbH & Co) bisoprolol were investigated in open-label cross-over randomized comparative study. 32 patients (15 males and 17 females) with AH of 1 (66%) and 2 (34%) grades aged of 60 y.o. on average were involved. After 2 weeks of wash-out period original or generic bisoprolol 5 mg daily was prescribed. If necessary a dose of drug was doubled in two weeks. In patients with significant bradycardia (heart rate <55 bp/min) or atrioventricular block (1-2 degree) hydrochlorothiazide (HCT) 12.5-25 mg per day was added. There was another 2-week wash-out period between two active treatment periods.

Results. Systolic and diastolic blood pressure (SBP, DBP) as well as heart rate (HR) were decreased significantly after two weeks of treatment with original bisoprolol (∆SBP=13.8±8.9, ∆DBP=8.5±8.6 mmHg and ∆HR=9.9±13.7 bp/min). Generic medication also significantly reduced SBP, DBP and HR (∆SBP=10.1±10.3, ∆DBP=7.1±7.2 mmHg and ∆HR=9.3±9.4 bp/min). Target SBP/DBP levels were achieved in 62.5%/71.9% of patients in Concor group and in 43.7%/62.5% of patients in Bisogamma group. There was a tendency to additional SBP decrease in patients treated with bisoprolol at a dose of 10 mg and with HCT in Concor group (–5.1±7.4 mmHg; p<0.09) and in Bisogamma group (–5.2±7.9 mmHg; p<0.06). After 4 weeks of treatment target SBP/DBP levels were achieved in 90.1%/96.9% of patients in Concor group and 75%/84.4% patients in Bisogamma group. The investigated parameters did not change significantly in a period between the 4 and 6 weeks of treatment. Monotherapy with Concor and Bisogamma was effective in 84.4% in 62% of patients, respectively (p<0.05). After 6 weeks of treatment target SBP and DBP levels were achieved in 96.9% of patients in the both groups. Average daily doses of original and generic bisoprolol were 6.5 and 7.2 mg, respectively.

Conclusion. Generic bisoprolol demonstrated lower antihypertensive efficacy and similar tolerability in comparison with original bisoprolol. 

About the Authors

S. N. Tolpygina
State Research center of preventive medicine of Roszdrav, Moscow
Russian Federation


E. V. Shilova
State Research center of preventive medicine of Roszdrav, Moscow
Russian Federation


S. Y. Martsevich
State Research center of preventive medicine of Roszdrav, Moscow
Russian Federation


References

1. Лукина Ю.В., Деев А.Д, Дмитриева Н.А. и др. Сравнительное изучение нового препарата метопролола тартрата пролонгированного действия – эгилока ретард и оригинального препарата метопролола сукцината – беталока ЗОК у больных мягкой и умеренной артериальной гипертонией. РФК 2005;(3): 35-40.

2. Марцевич С.Ю., Кутишенко Н.П., Деев А.Д. и др. Изучение терапевтической эквивалентности двух препаратов амлодипина (оригинального и воспроизведенного) у больных артериальной гипертонией. Результаты двойного-слепого рандомизированного перекрестного исследования. РКЖ 2004;(4): 53-6.

3. Недогода С.В., Марченко И.В., Чаляби Т.А. Сравнительная антигипертензивная эффективность генериков ингибитора ангиотензинпревращающего фермента эналаприла-ренитека (энапа, эднита, инворила, энваса и энама) и стоимость лечения у больных гипертонической болезнью. Артериальная гипертензия 2000;(1):52-4.

4. Carter B.L., Noyes M.A., Demmler R.W. Differences in serum concentrations of and response to generic verapamil in the elderly. Pharmacotherapy 1993;13:359-68.

5. Марцевич С.Ю., Лукина Ю.В., Деев А.Д. и др. Сравнительное изучение комбинированных препаратов эналаприла малеата и гидрохлортиазида: «рениприла ГТ» и «коренитека» у больных мягкой и умеренной АГ. РФК 2005;(3):29-34.

6. Guidelines subcommittee. 1999 World Health Organization-international Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999;17:151-8.

7. Frishman W, Bryzinski B, Coulson L at al. A multifactorial trial design to assess combination therapy in hypertension. Arch Inter Med 1994;154:1461-18.

8. Марцевич С.Ю. β-адреноблокаторы в лечении гипертонической болезни – роль бисопролола (Конкора). РМЖ 2002;10(15):664-7.

9. Wood D, De Backer G, Faergeman O, et al. for the Second Joint Task Force of European and other Societiesy on Coronary Prevention: European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Network. Prevention of coronary heart disease in clinical prac￾tice. Eur Heart J 1998; 19:1434-503.

10. Gibbons RJ, Chatterjeee K, Daley J, et al. for the task force on practice guidelines, ACC/AHA/ACP-ASIM. Guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 1999; 33:2092-197.

11. Grundy SM, Ivor J, Benjamin IJ, et al. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-46.

12. Smith SC, Blair SN, Bonow RO, et al. AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001; 104:1577-9.

13. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. for the Third Joint Task Force of the European and other Societies on cardiovascular disease prevention in clinical practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24:1601-10.

14. Thakkar RB, Oparil S. What do international guidelines say about therapy. Hypertension 2001;19(Suppl. 3):S23-31.

15. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003; 289:2560-72.

16. Мешковский А.П. Место генериков в лекарственном обеспечении. Фарматека 2003;(3):103-4.


For citation:


Tolpygina S.N., Shilova E.V., Martsevich S.Y. COMPARATIVE EVALUATION OF EFFICACY AND TOLERABILITY OF ORIGINAL AND GENERIC BISOPROLOL IN PATIENTS WITH ARTERIAL HYPERTENSION 1-2 GRADE. Rational Pharmacotherapy in Cardiology. 2007;3(3):15-21. (In Russ.) https://doi.org/10.20996/1819-6446-2007-3-3-15-21

Views: 785


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)